ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Oncorus raises $79.5 million for oncolytic virotherapy for cancer

by Ryan Cross
August 24, 2019 | APPEARED IN VOLUME 97, ISSUE 33

 

Oncorus, a start-up in Cambridge, Massachusetts, that is developing oncolytic virus therapies, has raised $79.5 million in series B financing. The firm’s lead drug candidate is an engineered herpes simplex virus that will be injected directly into tumors with the goal of killing them. The virus is also programmed to produce five proteins—including IL-12 and checkpoint inhibitors of CTLA-4 and PD-1—intended to activate the immune system to kill tumors throughout the body. Oncorus will use the money to begin clinical trials in early 2020.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment